[PDF][PDF] Did targeted therapy fail cyclooxygenase too?
I Csiki, DH Johnson - Journal of clinical oncology, 2006 - Citeseer
There are considerable preclinical and clinical data showing that cyclooxygenase-2 (COX-2)
plays an important role in the pathogenesis of non–small-cell lung cancers (NSCLC). 1, 2 …
plays an important role in the pathogenesis of non–small-cell lung cancers (NSCLC). 1, 2 …
Protracted dosing of the lipophilic camptothecin analogue AR-67 in non-small cell lung cancer xenografts and humans
E Tsakalozou, ED Adane, Y Liang, SM Arnold… - Cancer chemotherapy …, 2014 - Springer
Purpose Although preclinical studies on camptothecin antitumor effect have demonstrated
the superiority of low-dose protracted dosing, these findings were not replicated in the clinic …
the superiority of low-dose protracted dosing, these findings were not replicated in the clinic …
COX-2 与EGFR 信号通路的联合抑制在晚期非小细胞肺癌治疗中的应用
邓汉宇, 王玺, 李刚, 刘琦, 林一丹 - 中国胸心血管外科临床杂志, 2016 - cqvip.com
非小细胞肺癌对表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKIs) 的耐药问题已成为研究的
热点. 最近研究发现EGFR 和COX-2 信号通路之间存在着复杂的相互联系和作用, 抑制COX-2 …
热点. 最近研究发现EGFR 和COX-2 信号通路之间存在着复杂的相互联系和作用, 抑制COX-2 …
A curve-free Bayesian decision-theoretic design for phase Ia/Ib trials considering both safety and efficacy outcomes
A curve-free, Bayesian decision-theoretic two-stage design is proposed to select biological
efficacious doses (BEDs) for phase Ia/Ib trials in which both toxicity and efficacy signals are …
efficacious doses (BEDs) for phase Ia/Ib trials in which both toxicity and efficacy signals are …
COX-2 inhibitors, a potential synergistic effect with antineoplastic drugs in lung cancer
W Hohenforst-Schmidt, K Domvri, N Zogas… - Oncomedicine, 2017 - oncm.org
Background: Lung cancer represents the leading cause of cancer-related deaths worldwide
and novel therapeutic approaches targeting crucial pathways are urgently needed to …
and novel therapeutic approaches targeting crucial pathways are urgently needed to …
光波/微波组合-EDTA 修复COX-2 抗原及其在乳腺癌的表达及意义
熊正文, 李伟, 黄勇, 李宏伟, 寻凤华… - 中国组织化学与细胞化学 …, 2010 - cqvip.com
目的观察不同抗原修复方法及修复液对COX-2 抗原表达的影响及其与乳腺癌临床病理特征的
关系. 方法用光波/微波, 高压锅结合枸椽酸缓冲液, EDTA 作抗原修复处理 …
关系. 方法用光波/微波, 高压锅结合枸椽酸缓冲液, EDTA 作抗原修复处理 …
环氧化酶-2 表达与老年人非小细胞肺癌临床病理特征的关系
段光军, 吴曙华, 胡华成, 邓敏 - 中华老年医学杂志, 2009 - cqvip.com
非甾体类抗炎药(NSAIDs) 作用靶点为环氧化酶, 环氧化酶是催化花生四烯酸转化为前列腺素的
限速酶. 目前已被证实至少有2 种同工酶COX-1 和COX-2. COX-2 被认为是诱导型反应基因 …
限速酶. 目前已被证实至少有2 种同工酶COX-1 和COX-2. COX-2 被认为是诱导型反应基因 …
Cyclooxygenase 2 inhibition in patients with non–small cell lung cancer: Is this still a valid target for therapy?
SM Gadgeel - Cancer, 2015 - Wiley Online Library
In a randomized trial, the combination of the cyclooxygenase 2 (COX‐2) inhibitor celecoxib
with erlotinib demonstrated improved progression‐free survival in patients with elevated …
with erlotinib demonstrated improved progression‐free survival in patients with elevated …
The role of celecoxib as a COX-2 inhibitor increasing the radiosensitivity of tumor tissue
Y Jalalabadi, A Shirazi… - British Journal of …, 2015 - stm.e4journal.com
One of the major causes of death in the world is cancer. Due to significant advances in
molecular and cellular biology, previous approaches in cancer treatment have progressed …
molecular and cellular biology, previous approaches in cancer treatment have progressed …